The Small Animal Cancer Imaging Research Facility (SACIRF) provides cancer investigators with the latest technology and techniques for experimental in vivo imaging of small animals. The facility includes state-ofthe- art instrumentation, including the modalities of magnetic resonance (MR, Bruker4.7 T, 40 cm Biospec), x-ray computed tomography (micro-CT from Enhanced Vision Systems and volume CT being developed in collaboration with General Electric), projection radiography (Faxitron), and nuclear imaging (M.Cam gamma camera from Siemens and micro-PET from Concorde Microsystems). Optical imaging will be added during the first year of the award (instrumentation to be developed in collaboration with Biomedical Engineering at The University of Texas-Austin). This instrumentation represents a >$3M investment by MDACC. The SACIRF has allocated space for the instruments in the animal support facilities to facilitate the inclusion of the imaging studies in ongoing cancer research, and dedicated office and developmental laboratory space to support the facility operation. The faculty and staff are well-qualified in each of the modality areas, including current image acquisition and image analysis techniques. Specialty areas include quantitative tissue characterization (MR), imaging of microvascular physiology (MR, nuclear, CT and optical), diffusion imaging for estimating cellular density (MR), metabolic imaging (nuclear, positron emission tomography [PET], optical and MR spectroscopy), and vascular imaging (MR, CT, and x-ray). The services of the facility include imaging protocol design, custom positioning systems, custom data acquisition hardware and software, image analysis, data archiving, provision of hardcopy and digital data delivery, and database maintenance. The Veterinary Core includes a dedicated support team that provides highly efficient imaging studies and a very low mortality rate of animals during the imaging procedures. Services provided from the Veterinary Core include development of veterinary support protocols specific to each experimental design, and consultation on the inclusion of imaging procedures into existing protocols to obtain Institutional Animal Care and Use Committee approval. To date, 75 investigators representing 13 programs have used facility instrumentation. 42% of the users are peer-review-funded investigators. Utilization continues to increase as the facility and its capabilities become better known to the local cancer research community. The capabilities of the facility continue to grow to meet experimental demands. Publications are evolving at a rapid pace, and although only a few are published, the acceptance rate has been nearly 100%. Funding for the SACIRF is currently CCSG (43%), user fees (36%), and MDACC (21%).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-37
Application #
8379465
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
37
Fiscal Year
2012
Total Cost
$236,872
Indirect Cost
$83,063
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Liu, Yunhua; Xu, Hanchen; Van der Jeught, Kevin et al. (2018) Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer. J Clin Invest 128:2951-2965
Ferguson, Sherise D; Zheng, Siyuan; Xiu, Joanne et al. (2018) Profiles of brain metastases: Prioritization of therapeutic targets. Int J Cancer 143:3019-3026
Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194
Takahashi, Koichi; Wang, Feng; Morita, Kiyomi et al. (2018) Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun 9:2670
Yazbeck, Victor; Shafer, Danielle; Perkins, Edward B et al. (2018) A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk 18:569-575.e1
Kaushik, S; Liu, F; Veazey, K J et al. (2018) Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML. Leukemia 32:499-509
Trujillo-Ocampo, Abel; Cho, Hyun-Woo; Herrmann, Amanda C et al. (2018) Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease. Cytotherapy 20:1089-1101
Zhang, Peijing; Xiao, Zhenna; Wang, Shouyu et al. (2018) ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. Cell Rep 23:823-837
Das, Prosun; Veazey, Kylee J; Van, Hieu T et al. (2018) Histone methylation regulator PTIP is required to maintain normal and leukemic bone marrow niches. Proc Natl Acad Sci U S A 115:E10137-E10146
Jeter, Melenda D; Gomez, Daniel; Nguyen, Quynh-Nhu et al. (2018) Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A P Int J Radiat Oncol Biol Phys 100:730-737

Showing the most recent 10 out of 12418 publications